These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 9598777)
21. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Green M; Choules G; Rogers D; Titball RW Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452 [TBL] [Abstract][Full Text] [Related]
22. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure. Sutera V; Hoarau G; Renesto P; Caspar Y; Maurin M Int J Antimicrob Agents; 2017 Sep; 50(3):377-383. PubMed ID: 28689870 [TBL] [Abstract][Full Text] [Related]
24. [In Vitro Activity of Tigecycline Against Francisella tularensis Subsp. holarctica in Comparison with Doxycycline, Ciprofloxacin and Aminoglycosides]. Ulu Kılıç A; Kılıç S; Celebi B; Sencan I Mikrobiyol Bul; 2013 Jan; 47(1):189-91. PubMed ID: 23390918 [TBL] [Abstract][Full Text] [Related]
25. Antimicrobial Susceptibility of Francisella tularensis Isolates in the United States, 2009-2018. Choat J; Young J; Petersen JM; Dietrich EA Clin Infect Dis; 2024 Jan; 78(Suppl 1):S4-S6. PubMed ID: 38294116 [TBL] [Abstract][Full Text] [Related]
26. Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden. Plymoth M; Lundqvist R; Nystedt A; Sjöstedt A; Gustafsson TN Clin Infect Dis; 2024 May; 78(5):1222-1231. PubMed ID: 38393822 [TBL] [Abstract][Full Text] [Related]
27. Hunting for tularaemia - a review of cases in North Carolina. Rimawi RH; Shah KB; Chowdhary RA; Cook PP Zoonoses Public Health; 2015 May; 62(3):159-64. PubMed ID: 24655540 [TBL] [Abstract][Full Text] [Related]
28. The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy. Hamblin KA; Wong JP; Blanchard JD; Atkins HS Front Cell Infect Microbiol; 2014; 4():79. PubMed ID: 24995163 [TBL] [Abstract][Full Text] [Related]
29. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Conley J; Yang H; Wilson T; Blasetti K; Di Ninno V; Schnell G; Wong JP Antimicrob Agents Chemother; 1997 Jun; 41(6):1288-92. PubMed ID: 9174185 [TBL] [Abstract][Full Text] [Related]
30. A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis. Sutera V; Caspar Y; Boisset S; Maurin M Front Cell Infect Microbiol; 2014; 4():36. PubMed ID: 24672776 [TBL] [Abstract][Full Text] [Related]
31. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. Ikäheimo I; Syrjälä H; Karhukorpi J; Schildt R; Koskela M J Antimicrob Chemother; 2000 Aug; 46(2):287-90. PubMed ID: 10933655 [TBL] [Abstract][Full Text] [Related]
32. [The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia]. D'iakov SI; Bubnov VP; Lebedeva IK; Sidorenko SV; Moskalenko VI Antibiot Khimioter; 2000; 45(6):17-20. PubMed ID: 10904804 [TBL] [Abstract][Full Text] [Related]
33. In vitro antibiotic susceptibility of Francisella tularensis isolates from Japan. Hotta A; Fujita O; Uda A; Sharma N; Tanabayashi K; Yamamoto Y; Yamada A; Morikawa S Jpn J Infect Dis; 2013; 66(6):534-6. PubMed ID: 24270145 [TBL] [Abstract][Full Text] [Related]
34. New anti-infective strategies for treatment of tularemia. Maurin M Front Cell Infect Microbiol; 2014; 4():115. PubMed ID: 25191647 [No Abstract] [Full Text] [Related]
35. [Late recurrence of endocarditis caused by Coxiella burnetii following prosthetic valve substitution and prolonged antibiotic treatment]. Abril V; Ortega E; Segarra P; Fraile T Enferm Infecc Microbiol Clin; 1999 Jan; 17(1):44-5. PubMed ID: 10069116 [No Abstract] [Full Text] [Related]
36. Global transcriptomic analysis of Francisella tularensis SchuS4 differentially expressed genes in response to doxycycline or ciprofloxacin exposure. Zaide G; Cohen-Gihon I; Shifman O; Israeli O; Aftalion M; Maoz S; Chitlaru T; Ber R; Zvi A; Steinberger-Levy I BMC Genom Data; 2023 Apr; 24(1):23. PubMed ID: 37076811 [TBL] [Abstract][Full Text] [Related]
37. Treatment of tularemia with ciprofloxacin. Chocarro A; Gonzalez A; Garcia I Clin Infect Dis; 2000 Aug; 31(2):623. PubMed ID: 10987739 [No Abstract] [Full Text] [Related]
38. [Protective properties of doxycycline, rifampicin and sisomycin in experimental pulmonary tularemia of albino mice]. D'iakov SI; Bubnov VP; Lebedeva IK; Sidorenko SV; Moskalenko VI Antibiot Khimioter; 1998; 43(3):22-6. PubMed ID: 9606493 [TBL] [Abstract][Full Text] [Related]
39. Tularaemia in Minnesota: case report and brief epidemiology. Scheftel JM; Griffith JM; Leppke BA; Pantlin GC; Snippes PM; Wünschmann A Zoonoses Public Health; 2010 Dec; 57(7-8):e165-9. PubMed ID: 20163576 [TBL] [Abstract][Full Text] [Related]
40. Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones. Widerström M; Mörtberg S; Magnusson M; Fjällström P; Johansson AF Clin Infect Dis; 2024 Jan; 78(Suppl 1):S38-S46. PubMed ID: 38294118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]